Prestige Consumer Healthcare Inc. (PBH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.25% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- PBH vs. NEOG: Which Stock Is the Better Value Option?
- Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings?
- Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 Targets
- Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
- PBH or NEOG: Which Is the Better Value Stock Right Now?
- Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
- Is This the Right Time to Add PBH Stock to Your Portfolio?
- PBH vs. SYK: Which Stock Is the Better Value Option?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Prestige Consumer Healthcare Inc..
Full PBH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.